Pharmacokinetics of Bocidelpar in Hepatic Impairment

Phase 1, open-label trial of bocidelpar in Duchenne muscular dystrophy (DMD) and primary mitochondrial myopathy (PMM) (3 arms), sponsored by Astellas Pharma. Primary endpoints: Area Under The Concentration-time Curve From Time of Dosing Extrapolated to Time Infinity up to 5 days, Area Under Concentration-time Curve From Time of Dosing to the Last Measurable Concentration up to 5 days and 1 more. Started Sep 2021; status: completed.